Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735052) titled 'Drug-drug Interaction Study Between UIC202304, and UIC202305' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Other. Masking: None (Open Label).

Primary Sponsor: Korea United Pharm. Inc.

Condition: Healhty

Intervention: Drug: UIC202304 and co-administration of UIC202304 and UIC202305

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 25, 2023

Target Sample Size: 40

Countries of Recruitment: South Korea

To know more, visit https://clinicaltrials.gov/study/NCT07735052

Published by ...